Abstract

BackgroundAccess to adequate treatment for opioid use disorder (OUD) has been a high priority among American policymakers. Elucidation of the sociodemographic and institutional differences associated with the use, or lack thereof, of opioid agonist therapy (OAT) provides greater clarity on who receives OAT. Timely access to care is a further consideration and bears scrutiny as well.MethodsWe draw upon data from the Treatment Episode Data Set—Admissions (TEDS-A) to analyse the relationship between sociodemographic and institutional characteristics and the receipt of opioid agonist treatments and time waiting to enter treatment.ResultsEstimates from logistic regression models highlight certain groups which show lower odds of receipt of OAT, including those in precarious housing arrangements, those unemployed or not otherwise in the labor force, and those referred by drug abuse care providers, educational institutions, employers, and the criminal justice system. Groups which showed higher odds of waiting over a week to enter treatment included those who were separated, divorced, or widowed, those working part-time, and those referred by drug abuse care providers, employers, and the criminal justice system.ConclusionGiven the efficacy of OAT and the adverse outcomes associated with long waiting times, coordinated effort is needed to understand why these differences persist and how they may be addressed through appropriate policy responses.

Highlights

  • In 2010 the global burden of disease attributable to opioid dependence was 9.2 million disability-adjusted life years (DALYs) with 15.5 million individuals suffering from opioid dependence and a significantly high burden of premature mortality affecting North America and Eastern Europe [1]

  • We draw upon data from the Treatment Episode Data Set—Admissions (TEDS-A) to analyse the relationship between sociodemographic and institutional characteristics and the receipt of opioid agonist treatments and time waiting to enter treatment

  • Given the efficacy of opioid agonist therapy (OAT) and the adverse outcomes associated with long waiting times, coordinated effort is needed to understand why these differences persist and how they may be addressed through appropriate policy responses

Read more

Summary

Introduction

In 2010 the global burden of disease attributable to opioid dependence was 9.2 million disability-adjusted life years (DALYs) with 15.5 million individuals suffering from opioid dependence and a significantly high burden of premature mortality affecting North America and Eastern Europe [1]. The opioid epidemic in the United States has been one of the most pressing public health challenges identified by the United States Centers for Disease Control and Prevention (CDC) [2], involving both heroin use, proved to be exacerbated by socioeconomic vulnerability [3], as well as ease of accessibility and over prescription of synthetic opioids such as oxycodone and fentanyl, respectively, which appear to fuel the increasing toxicity and mortality of these substances [4]. Access to care is a further consideration and bears scrutiny as well

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call